Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
For instance, after initial treatment with IV alemtuzumab, with or without pentostatin
Related Questions
For patients with newly diagnosed AML who are induction chemotherapy eligible, do you dose reduce cytarabine for any mild elevation in AST/ALT?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL.
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
Does treating CLL reduce the risk of non-melanoma skin cancers?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?